Susan Burdette-Radoux

1.6k total citations
26 papers, 1.2k citations indexed

About

Susan Burdette-Radoux is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Susan Burdette-Radoux has authored 26 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 7 papers in Cancer Research and 6 papers in Molecular Biology. Recurrent topics in Susan Burdette-Radoux's work include Breast Cancer Treatment Studies (7 papers), Cancer Treatment and Pharmacology (6 papers) and HER2/EGFR in Cancer Research (6 papers). Susan Burdette-Radoux is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Cancer Treatment and Pharmacology (6 papers) and HER2/EGFR in Cancer Research (6 papers). Susan Burdette-Radoux collaborates with scholars based in United States, Canada and United Kingdom. Susan Burdette-Radoux's co-authors include Hyman B. Muss, Ian Quirt, Johannes Nippgen, David Schiff, Burt Nabors, Edward J. Dropcho, William R. Shapiro, Karen Fink, Martin Picard and David A. Reardon and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Susan Burdette-Radoux

25 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susan Burdette-Radoux United States 12 470 461 224 212 158 26 1.2k
Steven Pirie‐Shepherd United States 19 815 1.7× 356 0.8× 99 0.4× 398 1.9× 148 0.9× 36 1.4k
Francesco Atzori Italy 13 776 1.7× 435 0.9× 151 0.7× 219 1.0× 270 1.7× 62 1.4k
Magdalena Koziczak Switzerland 8 786 1.7× 703 1.5× 84 0.4× 311 1.5× 156 1.0× 9 1.4k
Kazushi Shigemasa Japan 27 840 1.8× 636 1.4× 421 1.9× 441 2.1× 98 0.6× 50 1.8k
Tiffany K. Ricks United States 15 542 1.2× 781 1.7× 158 0.7× 162 0.8× 206 1.3× 21 1.8k
Iwan Beuvink Switzerland 11 1.1k 2.4× 840 1.8× 86 0.4× 304 1.4× 204 1.3× 13 1.7k
Michele Massimino Italy 22 496 1.1× 297 0.6× 339 1.5× 249 1.2× 131 0.8× 64 1.2k
Massimo Fanelli Italy 17 555 1.2× 423 0.9× 84 0.4× 310 1.5× 118 0.7× 26 1.0k
Rajiv Bassi United States 19 925 2.0× 783 1.7× 105 0.5× 280 1.3× 373 2.4× 26 1.7k
Hamid Masoudi Canada 17 741 1.6× 663 1.4× 119 0.5× 228 1.1× 125 0.8× 28 1.6k

Countries citing papers authored by Susan Burdette-Radoux

Since Specialization
Citations

This map shows the geographic impact of Susan Burdette-Radoux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Burdette-Radoux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Burdette-Radoux more than expected).

Fields of papers citing papers by Susan Burdette-Radoux

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Burdette-Radoux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Burdette-Radoux. The network helps show where Susan Burdette-Radoux may publish in the future.

Co-authorship network of co-authors of Susan Burdette-Radoux

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Burdette-Radoux. A scholar is included among the top collaborators of Susan Burdette-Radoux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Burdette-Radoux. Susan Burdette-Radoux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Yunhong, Sudhamshi Toom, Susan Burdette-Radoux, et al.. (2021). Clinical Determinants Differentiating the Severity of SARS-CoV-2 Infection in Cancer Patients: Hospital Care or Home Recovery. Frontiers in Medicine. 8. 604221–604221. 3 indexed citations
2.
3.
Burdette-Radoux, Susan & Hyman B. Muss. (2009). A Question of Duration: Do Patients with Early-Stage Breast Cancer Need More Than Five Years of Adjuvant Endocrine Therapy?. Clinical Breast Cancer. 9. S37–S41. 9 indexed citations
4.
Govindan, Ramaswamy, Xiaofei Wang, Maria Q. Baggstrom, et al.. (2009). A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104. Journal of Thoracic Oncology. 4(2). 220–226. 11 indexed citations
5.
6.
7.
Burdette-Radoux, Susan, et al.. (2007). Phase I/II Trial of Adjuvant Dose-Dense Docetaxel/Epirubicin/Cyclophosphamide (TEC) in Stage II and III Breast Cancer. The Breast Journal. 13(3). 274–280. 10 indexed citations
8.
Grunberg, Steven M., et al.. (2007). Efficacy of a 1-day 3-drug antiemetic regimen for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy. Journal of Clinical Oncology. 25(18_suppl). 9111–9111. 5 indexed citations
9.
Krag, David N., Girja S. Shukla, Guang‐Ping Shen, et al.. (2006). Selection of Tumor-binding Ligands in Cancer Patients with Phage Display Libraries. Cancer Research. 66(15). 7724–7733. 165 indexed citations
10.
Burdette-Radoux, Susan & Hyman B. Muss. (2006). Adjuvant Chemotherapy in the Elderly: Whom to Treat, What Regimen?. The Oncologist. 11(3). 234–242. 28 indexed citations
11.
Crott, Ralph, et al.. (2004). Cost–Utility of Adjuvant High-Dose Interferon Alpha Therapy in Stage III Cutaneous Melanoma in Quebec. Value in Health. 7(4). 423–432. 17 indexed citations
12.
Burdette-Radoux, Susan, Richard Tozer, Reinhard Lohmann, et al.. (2004). Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Investigational New Drugs. 22(3). 315–322. 72 indexed citations
13.
Bélanger, Karl, David R. Macdonald, Gregory Cairncross, et al.. (2003). A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. Investigational New Drugs. 21(4). 473–480. 3 indexed citations
14.
Rose, Carsten, A Płużańska, Nancy E. Davidson, et al.. (2003). An open randomised trial of second-line endocrine therapy in advanced breast cancer. European Journal of Cancer. 39(16). 2318–2327. 145 indexed citations
15.
Burdette-Radoux, Susan & Hyman B. Muss. (2003). Optimizing the Use of Anthracyclines in the Adjuvant Treatment of Early-Stage Breast Cancer. Clinical Breast Cancer. 4(4). 264–272. 5 indexed citations
16.
Quirt, Ian, Michael J. Kovacs, Susan Burdette-Radoux, et al.. (2002). Epoetin alfa in patients not on chemotherapy [ndash ] Canadian data. Seminars in Oncology. 29(3 Suppl 8). 75–80. 3 indexed citations
17.
Tozer, Richard, Susan Burdette-Radoux, M. L. Davis, et al.. (2002). A Randomized Phase II Study of Two Schedules of Bryostatin-1 (NSC339555) in Patients with Advanced Malignant Melanoma – A National Cancer Institute of Canada Clinical Trials Group Study. Investigational New Drugs. 20(4). 407–412. 18 indexed citations
18.
Bélanger, K., Richard Tozer, Susan Burdette-Radoux, et al.. (1999). Results of a randomized phase II study of two schedules of bryostatin-I in patients with malignant melanoma: experience with the multivariate stopping rule. European Journal of Cancer. 35. S374–S374. 2 indexed citations
19.
Leyland‐Jones, Brian & Susan Burdette-Radoux. (1997). Management of hepatic metastases from colorectal cancer: systemic chemotherapy. Journal of Gastrointestinal Surgery. 1(6). 576–582. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven Pirie‐Shepherd Breakdown of academic impact, for papers by Francesco Atzori Breakdown of academic impact, for papers by Magdalena Koziczak Breakdown of academic impact, for papers by Kazushi Shigemasa Breakdown of academic impact, for papers by Tiffany K. Ricks Breakdown of academic impact, for papers by Iwan Beuvink Breakdown of academic impact, for papers by Michele Massimino Breakdown of academic impact, for papers by Massimo Fanelli Breakdown of academic impact, for papers by Rajiv Bassi Breakdown of academic impact, for papers by Hamid Masoudi
Rankless by CCL
2026